Armistice Capital’s CRISPR Therapeutics CRSP Stock Holding History

Armistice Capital’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-208,000	Closed	-$8.19M	–	240
2024 Q4	$8.19M	Buy	208,000 +8,000	+4%	+$378K	0.11%	102
2024 Q3	$9.4M	Buy	200,000 +1,643	+0.8%	+$83.4K	0.15%	97
2024 Q2	$10.7M	Buy	198,357 +6,357	+3%	+$368K	0.13%	88
2024 Q1	$13.1M	Buy	192,000 +24,000	+14%	+$1.72M	0.17%	87
2023 Q4	$10.5M	Sell	168,000 -432,012	-72%	-$23.9M	0.14%	81
2023 Q3	$27.2M	Buy	600,012 +100,012	+20%	+$5.17M	0.42%	48
2023 Q2	$28.1M	Sell	500,000 -324,000	-39%	-$18.4M	0.41%	50
2023 Q1	$37.3M	Sell	824,000 -212,000	-20%	-$10.3M	0.54%	42
2022 Q4	$42.1M	Buy	1,036,000 +112,000	+12%	+$5.94M	0.73%	33
2022 Q3	$60.4M	Sell	924,000 -76,000	-8%	-$5.51M	1.05%	22
2022 Q2	$60.8K	Sell	1,000,000 -24,000	-2%	-$1.41M	1.06%	25
2022 Q1	$64.3M	Buy	1,024,000 +132,000	+15%	+$8.29M	1.24%	16
2021 Q4	$67.6M	Buy	892,000 +512,000	+135%	+$44.7M	1.11%	20
2021 Q3	$42.5M	Buy	380,000 +222,000	+141%	+$27.9M	0.72%	33
2021 Q2	$25.6M	Buy	158,000 +2,000	+1%	+$243K	0.46%	59
2021 Q1	$19M	Buy	156,000 +84,000	+117%	+$12.7M	0.44%	57
2020 Q4	$11M	Sell	72,000 -132,000	-65%	-$15.6M	0.37%	67
2020 Q3	$17.1M	Buy	204,000 +16,000	+9%	+$1.42M	0.62%	52
2020 Q2	$13.8M	Sell	188,000 -48,000	-20%	-$2.81M	0.61%	57
2020 Q1	$10M	Buy	236,000 +88,000	+59%	+$4.54M	0.62%	53
2019 Q4	$9.01M	Sell	148,000 -116,000	-44%	-$6.33M	0.52%	50
2019 Q3	$10.8M	Buy	+264,000	New	+$12.6M	0.72%	40
2019 Q2	–	Sell	-80,000	Closed	-$2.86M	–	66
2019 Q1	$2.86M	Sell	80,000 -92,000	-53%	-$3.18M	0.16%	62
2018 Q4	$4.91M	Buy	+172,000	New	+$5.98M	0.37%	50
2018 Q3	–	Sell	-124,000	Closed	-$7.29M	–	82
2018 Q2	$7.29M	Buy	+124,000	New	+$7.06M	0.48%	53

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Armistice Capital's CRSP Position: Q1 2025 in Review

Armistice Capital sold out of CRISPR Therapeutics (CRSP) in Q1 2025, closing a stake of 208,000 shares — an estimated $8.19M sold.

Armistice Capital first reported a position in CRSP in Q2 2018 and held it in 25 quarters. The position peaked at $67.6M in Q4 2021. 396 funds tracked by Wall St. Rank hold CRSP as of Q1 2025.

Armistice Capital reported no remaining CRISPR Therapeutics position as of Q1 2025 after selling out during the quarter.
Armistice Capital sold 208,000 CRISPR Therapeutics shares in Q1 2025, an estimated $8.19M.
Armistice Capital first reported a position in CRISPR Therapeutics in Q2 2018 and held it in 25 quarters.
Armistice Capital's CRISPR Therapeutics position peaked at $67.6M in Q4 2021.
396 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2025.

Based on Armistice Capital's 13F filing for Q1 2025, filed 15 May 2025.